- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Gillian Woollett Highlights International Markets With Successful Biosimilar Adoption
Gillian Woollett, MA, Dphil, vice president and head of regulatory strategy and policy at Samsung Bioepis, gives insight into what international markets the United States could look to as examples of good biosimilar adoption.
Gillian Woollett, MA, Dphil, vice president and head of regulatory strategy and policy at Samsung Bioepis, gives insight into what international markets the United States could look to as examples of good biosimilar adoption at the Festival of Biologics 2022 meeting in San Diego, California.
Transcript
Besides Europe, what other markets should the US look to as examples of good biosimilar adoption?
Well, Canada came up a little bit on the adoption because they've been most proactive on ideas around switching. So, the issues on switching of patients, whether they're on the originator or on another biosimilar, were discussed, and I don't think anybody really had a basis for clinical concerns given all the data that's accruing. But there's definitely an expectation that switching from [the] reference to biosimilar is somehow different than between biosimilars even though all of them would be under the auspices of a physician's prescription given that, basically, we haven't had [much experience with] interchangeables yet, at any level, even in the United States, and we don't have interchangeables anywhere else in the world. There was actually a presentation from Denmark that also gave a lot of their experience. So, that's useful; they've been actively switching.
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More
Early Detection Strategies for Interstitial Lung Disease in Rheumatology: Janet Pope, MD, MPH
August 11th 2025Janet Pope, MD, MPH, discusses screening and diagnostic approaches for interstitial lung disease in patients with systemic sclerosis, rheumatoid arthritis, and other connective tissue diseases.
Read More
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen
AI Meets Medicare: Inside CMS’s WISeR Model With Sanjay Doddamani, MD, MBA, Part 2
August 5th 2025In this second part of his interview with The American Journal of Managed Care®, Sanjay Doddamani, MD, MBA, a former senior advisor to CMMI and founder and CEO of Guidehealth, continues a dialogue on the future of value-based care and the promise—and limits—of AI-enabled innovation, reflecting on challenges like rising Medicare costs and patients’ growing financial burdens.
Read More
IgE Mediation in Pediatric Atopic Dermatitis, Concurrent Immune Disorders: Amy Paller, MD
August 4th 2025Amy Paller, MD, pediatric dermatologist and clinical researcher at Northwestern Medicine's Feinberg School of Medicine, discussed the potential impact of reducing immunoglobulin E (IgE) levels in pediatric patients with atopic dermatitis.
Read More
